Basic & Clinical Medicine ›› 2022, Vol. 42 ›› Issue (1): 159-162.doi: 10.16352/j.issn.1001-6325.2022.01.025

• Mini Reviews • Previous Articles     Next Articles

Research progress on IL-6/JAK/STAT3 in the development and treatment of prostate cancer

CHEN Hao1, CHEN Tao2, WU Jing1*   

  1. 1. Department of Biochemistry and Molecular Biology, Kunming Medical University, Kunming 650500;
    2. Department of Urology, the Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China
  • Received:2021-04-15 Revised:2021-08-13 Online:2022-01-05 Published:2022-01-05
  • Contact: * wujingkm176@126.com

Abstract: IL-6/JAK/STAT3 is one of the most significant signaling pathways activated by IL-6.IL-6 and p-STAT3 which are highly expressed in prostate cancer (PCa) tissue and metastatic tumors So this pathway may play a role in the occurrence of prostate cancer, promotion of malignant cell proliferation, invasion and metastasis of the tumor. It may also function in the development of castration resistance and drug resistance through activation androgen receptor(AR). The multiple roles of IL-6/JAK/STAT3 and its activated downstream factors in tumor progression provide a good basis for the development of chemotherapy drugs. Currently, many targeted inhibitors have been proved to be effective in inhibiting tumor progression and more effective drugs are expected to be developed.

Key words: prostate cancer, castration-resistant prostate cancer, interleukin-6, signal transducer and activator of transcription (STAT3)

CLC Number: